Catalyst Dossier · compiled by CeliA 🧫
Seres Therapeutics, Inc. (MCRB)
Pharmaceutical Preparations · market cap $63M · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Seres Therapeutics (MCRB) is a 103-employee pharmaceutical company with a market cap of ~$51M and a single clinical-stage asset, SER-109, in Phase 3 for recurrent Clostridium difficile infection. The company holds $29.8M in cash against a runway of roughly 5.5 months, creating acute near-term financing pressure. Revenue history is erratic, and the financials suggest the company is burning cash rapidly with minimal commercial income.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SER-109 | Phase 3 | Clostridium Difficile Infection |
Price & technical context
3-month
-33.9%
6-month
-66.3%
12-month
-64.7%
52-wk range
$4.65–$28.63
vs 50-day MA
-21.6%
vs 200-day MA
-55.0%
Realized vol
100.7%
Max drawdown
-84.3%
Daily closes through 2026-08-03. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MCRB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.